Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review

The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depres...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mateusz Kowalczyk, Edward Kowalczyk, Paweł Kwiatkowski, Łukasz Łopusiewicz, Monika Sienkiewicz, Monika Talarowska
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ketamine depression anxiety NMDA receptor neurodegeneration GABA Science Q
Acceso en línea:	https://doaj.org/article/ca4145ee1a4041a6a0c0ffd99daea105
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca4145ee1a4041a6a0c0ffd99daea105
record_format	dspace
spelling	oai:doaj.org-article:ca4145ee1a4041a6a0c0ffd99daea1052021-11-25T18:10:59ZKetamine—New Possibilities in the Treatment of Depression: A Narrative Review10.3390/life111111862075-1729https://doaj.org/article/ca4145ee1a4041a6a0c0ffd99daea1052021-11-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1186https://doaj.org/toc/2075-1729The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depressive episodes. An effective drug seems to be s-ketamine, which was accepted in March 2019 by the Food and Drug Administration (FDA) for the treatment of drug-resistant depression. This drug provides a quick antidepressant effect with maximum effectiveness achieved after 24 h. It also appears to reduce the occurrence of suicidal thoughts. However, research into undesirable effects, especially in groups of people susceptible to psychotic episodes or those who use alcohol or psychoactive substances, is necessary.Mateusz KowalczykEdward KowalczykPaweł KwiatkowskiŁukasz ŁopusiewiczMonika SienkiewiczMonika TalarowskaMDPI AGarticleketaminedepressionanxietyNMDA receptorneurodegenerationGABAScienceQENLife, Vol 11, Iss 1186, p 1186 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ketamine depression anxiety NMDA receptor neurodegeneration GABA Science Q
spellingShingle	ketamine depression anxiety NMDA receptor neurodegeneration GABA Science Q Mateusz Kowalczyk Edward Kowalczyk Paweł Kwiatkowski Łukasz Łopusiewicz Monika Sienkiewicz Monika Talarowska Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
description	The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depressive episodes. An effective drug seems to be s-ketamine, which was accepted in March 2019 by the Food and Drug Administration (FDA) for the treatment of drug-resistant depression. This drug provides a quick antidepressant effect with maximum effectiveness achieved after 24 h. It also appears to reduce the occurrence of suicidal thoughts. However, research into undesirable effects, especially in groups of people susceptible to psychotic episodes or those who use alcohol or psychoactive substances, is necessary.
format	article
author	Mateusz Kowalczyk Edward Kowalczyk Paweł Kwiatkowski Łukasz Łopusiewicz Monika Sienkiewicz Monika Talarowska
author_facet	Mateusz Kowalczyk Edward Kowalczyk Paweł Kwiatkowski Łukasz Łopusiewicz Monika Sienkiewicz Monika Talarowska
author_sort	Mateusz Kowalczyk
title	Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
title_short	Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
title_full	Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
title_fullStr	Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
title_full_unstemmed	Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
title_sort	ketamine—new possibilities in the treatment of depression: a narrative review
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ca4145ee1a4041a6a0c0ffd99daea105
work_keys_str_mv	AT mateuszkowalczyk ketaminenewpossibilitiesinthetreatmentofdepressionanarrativereview AT edwardkowalczyk ketaminenewpossibilitiesinthetreatmentofdepressionanarrativereview AT pawełkwiatkowski ketaminenewpossibilitiesinthetreatmentofdepressionanarrativereview AT łukaszłopusiewicz ketaminenewpossibilitiesinthetreatmentofdepressionanarrativereview AT monikasienkiewicz ketaminenewpossibilitiesinthetreatmentofdepressionanarrativereview AT monikatalarowska ketaminenewpossibilitiesinthetreatmentofdepressionanarrativereview
_version_	1718411523731226624

Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review

Ejemplares similares